Facebook Twitter LinkedIn
PERPercheron
April 28, 2026

Percheron Therapeutics (ASX:PER): 2026 will be a year of major strides

Percheron Therapeutics (ASX:PER) is a clinical-stage Australian immuno-oncology company which is progressing to Phase 2 in 2026. The magic of supressing VISTA HMBD-002, is a monoclonal antibody targeting VISTA, a next-generation immune checkpoint. VISTA can suppress T-cell responses to cancer treatments and the idea is that by ‘drugging VISTA’, cancer treatments can be more efficacious. […]
Read More
Dimerix
April 21, 2026

Dimerix (ASX:DXB): A pivotal time is ahead!

Over the past few years Dimerix (ASX:DXB) has established all the building blocks in place to commercialise DMX-200 (known in some markets as Qytovra). DXB has gathered extensive clinical data, signed 4 commercial arrangements which provide not just paths to market but also validation and sources of non-dilutive funding in signature and milestone payments (up […]
Read More
Environmental Clean Technologies
Environmental Clean TechnologiesECT
April 9, 2026

Environmental Clean Technologies (ASX:ECT): PFAS is the “new asbestos” and the bill is coming due

On the 24th of December 2025, Environmental Clean Technologies (ASX:ECT) acquired the patent rights to Flash Joule Heating (FJH) technology for the remediation of PFAS in soil from Rice University. The technology was developed under Professor James Tour, who is widely recognised for pioneering this rapid heating method. ECT intends to deploy FJH to address […]
Read More
TemasTIOTemas Resources
March 25, 2026

Temas Resources Corp (ASX:TIO): Unique Mineral Processing Technology

Temas Resources is a recently ASX-listed technology and titanium play – joining the ASX in October 2025, but first listed on the Canadian Securities Exchange in 2020. Temas has a potentially breakthrough processing technology (Regenerative Chloride Leach or RCL) that can better recover metals from hard-to-process or complex ore, compared to other approaches. We see […]
Read More
Green360 TechnologiesGT3
March 24, 2026

Green360 Technologies (ASX:GT3): GT3’s inaugural toll-treatment agreement is signed

Green360 Technologies is a producer of kaolin and is developing a low-carbon cement replacement product known as Eco-Clay. Eco-Clay can replace up to 40% of conventional cement, without compromising the end application’s performance, while significantly reducing carbon emissions of finished concrete. This is achieved by the removal of processes emissions incurred in the burning of […]
Read More
Rhythm Biosciences
March 18, 2026

Rhythm Biosciences (ASX:RHY): ColoSTAT’s rollout is ramping up!

The dream Rhythm Biosciences (ASX:RHY) investors have held ever since the company listed in 2017 has been realised: ColoSTAT has been approved and commercialised, even if slightly different to what investors may have earlier anticipated. The ColoSTAT rollout has begun Rhythm Biosciences completed the first sale of ColoSTAT earlier this month, which represented not only […]
Read More
Prescient Therapeutics
healthbiotechPrescientPTXHealtj
March 17, 2026

Prescient Therapeutics (ASX:PTX): Ramping up patient enrolment

Prescient Therapeutics (ASX: PTX) is a clinical-stage oncology company whose lead asset, PTX-100, is the world’s first-in-class GGTase-1 inhibitor in clinical development — and, as of today, the only drug of its kind targeting relapsed/refractory cutaneous T-Cell Lymphona (CTCL), a very deadly form of cancer. Building a Phase 2 footprint Since our last note, published […]
Read More
Register for the Conference